FDA Issues Draft Guidance on Equity, Diversity and Individual Sponsor Financial Ability Considerations in Charging for Investigational Drugs | Akin Gump Strauss Hauer & Feld LLP

On August 23, 2022, the United States Food and Drug Administration (FDA or the “Agency”) published the revised draft guidance “Charging for Investigational Drugs Under an IND Questions...

Related Keywords

United States , ,Akin Gump Strauss Hauer Feld ,Drug Administration ,Akin Gump Strauss Hauer ,United States Food ,Investigational Drugs Under ,Answers Guidance ,Draft Guidance ,Sponsor Must Request ,Certified Public Accountant ,Anti Kickback Statute ,False Claims Act ,One Year Period ,